Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21038861 | 0.88 | MMP2 (0.33) | GAANPSR1POLBL3MBTL1UTS2R | |
| SCHEMBL22162655 | 0.85 | MMP2 (0.37) | GAANPSR1POLBL3MBTL1MEN1 | |
| SCHEMBL1324048 | 0.76 | POLB (0.42) | GAANPSR1POLBL3MBTL1CYP1A2 | |
| SCHEMBL22162310 | 0.73 | — | — | |
| SCHEMBL21038085 | 0.73 | ATM (0.30) | — | |
| SCHEMBL22883277 | 0.70 | — | — | |
| SCHEMBL7120289 | 0.69 | EGFR (0.41) | POLBHSD11B1MEN1CYP1A2TSHR | |
| SCHEMBL21038053 | 0.69 | GAA (0.35) | GAANPSR1 | |
| SCHEMBL21037560 | 0.67 | — | — | |
| SCHEMBL22386695 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11718599-B2 | Method for producing cyclic carbonate having unsaturated group, and novel cyclic carbonate | DAIKIN INDUSTRIES, LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11718599-B2 | Method for producing cyclic carbonate having unsaturated group, and novel cyclic carbonate | DAIKIN INDUSTRIES, LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| EP-3780230-B1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE | DAIKIN IND LTD (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11664534-B2 | Electrolytic solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-11664534-B2 | Electrolytic solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-20210384556-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210198228-A1 | METHOD FOR PRODUCING CYCLIC CARBONATE HAVING UNSATURATED GROUP, AND NOVEL CYCLIC CARBONATE | DAIKIN INDUSTRIES, LTD. (JP) | 2021-07-01 | — | — | US | disclosed |
| EP-3780230-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2021-02-17 | — | — | EP | disclosed |
| US-20210043974-A1 | ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3764451-A1 | ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-20200280096-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2020-09-03 | — | — | US | disclosed |
| EP-3670502-A1 | METHOD FOR PRODUCING CYCLIC CARBONATE HAVING UNSATURATED GROUP, AND NOVEL CYCLIC CARBONATE | Daikin Industries, Ltd. (JP) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019102722-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | ダイキン工業株式会社 | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200280096-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | RER1, NDUFA10, NDUFB10 | GAA 2965/4885NPSR1 4054/4885POLB 185/4885 |
| US-11718599-B2 | Method for producing cyclic carbonate having unsaturated group, and novel cyclic carbonate | ADH1C, ADH1A, F12 | GAA 4260/4885NPSR1 1935/4885POLB 1385/4885 |
| US-11664534-B2 | Electrolytic solution, electrochemical device, lithium ion secondary battery, and module | RER1, NDUFA10, NDUFB10 | GAA 2965/4885NPSR1 4054/4885POLB 185/4885 |
| US-20210198228-A1 | METHOD FOR PRODUCING CYCLIC CARBONATE HAVING UNSATURATED GROUP, AND NOVEL CYCLIC CARBONATE | ADH1C, ADH1A, F12 | GAA 4260/4885NPSR1 1935/4885POLB 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.